Scaling Cell and Gene Therapy Manufacturing for Global Commercialization

The Cell and Gene Therapy Factory Has Become the Commercial Strategy

American pharma executives rarely lose sleep over whether cell and gene therapy works. The harder question is whether it can behave like a business at global scale. Approved products have produced responses that earlier generations of oncologists could only hope for, yet many of them reach only a sliver of eligible patients.

Manufacturing sits at the center of that gap, and it is often misread as a matter for the technical operations team. In this field, the network determines who can be treated, how quickly, at what margin and in how many countries. Several forces have converged in 2026 to make those decisions urgent: a more flexible FDA, a new trade and biosecurity regime, expanding payer models and a credible challenge from therapies that may need no cell factory at all.

The 5.4% Problem: Where Cell Therapy Manufacturing Meets the Patient

A SEER-Medicare analysis found that only 5.4% of patients with relapsed or refractory diffuse large B-cell lymphoma receiving third-line or later therapy were treated with CAR-T. Each additional 10 miles from a treating center lowered the likelihood of treatment by 6.2%. Regulators have removed one barrier: in June 2025, FDA eliminated the REMS for approved autologous BCMA- and CD19-directed CAR-T therapies and cut the required stay near a treatment center from one month to two weeks, opening a path toward community settings.

That shifts pressure back onto supply. Community oncology cannot absorb a therapy whose slot is uncertain or whose delivery takes weeks. Commercial products show median vein-to-vein times of 30.6 to 48.4 days, and a time of 40 days or more, compared with under 28, has been associated with worse overall survival. In one myeloma waitlist analysis, only 60% of patients obtained a manufacturing slot. Turnaround time therefore deserves a place in board-level reporting.

Autologous Cell Therapy Does Not Scale Up. It Scales Out.

Antibody logic says a bigger tank lowers unit cost. Autologous therapy refuses that logic, because each batch remains one patient. Capacity grows by adding parallel suites, people and quality reviewers, with published reviews reporting more than 200 labor hours per batch. Cost and risk rise nearly in step with output.

The strategic choice lies between a few large hubs and a distributed network. Hospital-based programs using short automated processes have repeatedly reported vein-to-vein times of 9 to 15 days, with response and toxicity rates in the range of commercial registration trials, though cross-trial comparisons carry obvious limits. Those results do not settle the matter for a US sponsor, since a distributed model must demonstrate comparability across every site under one quality system. A hybrid looks the more likely destination: central control of vector and critical materials, regional hubs for core volume and carefully qualified near-patient capacity for markets a hub cannot reach in time.

The Automation Mirage in Cell Therapy Cost of Goods

Automation is usually presented as the cure, and vendor claims of deep savings deserve independent scrutiny. One 2025 facility model estimated a cost per treatment of about €63,000 with manual processes and €57,000 with full automation, roughly a 10% improvement, while reagents made up more than half of cost of goods. Vector and quality control testing have separately been identified as the main cost drivers.

Automation buys consistency, throughput and workforce relief, which may matter more than the direct cost line. Larger gains may lie elsewhere. Release testing commonly adds two to three weeks, while rapid nucleic acid mycoplasma assays return results in under five hours, against 28 days for the reference culture method. Sponsors that modernize analytics, renegotiate vector supply and qualify second sources may unlock more value than those who buy a robot and stop there.

Gene Therapy's Arithmetic of Empty Shells

AAV can use large bioreactors, but high systemic doses consume a great deal of vector, and batches often contain many capsids carrying no therapeutic payload. Low full-to-empty ratios remain a shared industry problem, with 80% full capsids before purification cited as one ambitious target. Many processes also rely on transient transfection, effectively a single-run system dependent on plasmid supply.

Stable producer cell lines promise a simpler, more repeatable process, but viral genes can be toxic to host cells, which has made these lines difficult to create and maintain. Timing is the executive question. Locking a process too early carries its cost into every future dose, while changing it late brings a comparability burden that can delay pivotal data. The most useful test for any gene therapy asset is blunt: at peak forecast demand, how many batches does this process require, and does the gross margin survive?

FDA's New CMC Latitude Is a Loan, Not a Gift

CBER's final guidance on CMC flexibilities for cell and gene therapies, issued this year, is a highly practical US shift. It sets no minimum number of process performance qualification batches, provided sponsors justify their number through process understanding and controls. Where production is limited, it allows concurrent release of those batches and, in some cases, completion after licensure. It also supports phase-appropriate CGMP, single-lot analytical method validation and limited comparability data for low-risk changes to investigational products.

It can speed the path to a license without lowering the eventual cost of a fragile process. A sponsor reaching approval with thin process knowledge may find the debt coming due when it adds a second site, files abroad or serves ten times the volume. Other agencies are under no obligation to accept the same logic. The better use of this latitude is to redirect saved time into process characterization rather than simply pulling the launch date forward.

One Therapy, 300 Rulebooks: The Global Commercialization Test

An ICH analysis identified more than 300 region-specific guidelines for advanced therapies among its members and observers. Its discussion group has proposed annexes on comparability and starting materials, plus a new nonclinical guideline, but harmonized text is unlikely to arrive in time for most current launch plans.

Approval is also no guarantee of a market. By 2023, seven of the 25 advanced therapies approved in Europe had been withdrawn for commercial reasons, and EU Joint Clinical Assessment has covered new advanced therapies since January 2025. Price widens the challenge. US list prices for autologous CAR-T ranged from $462,000 to $594,000 in 2025, while Spain's national system reimbursed an academic product at about $101,000 and an Indian analysis put point-of-care production near $35,000 per product, excluding vector. One cost structure cannot serve all those markets. US sponsors may need regional partners, technology transfer or tiered manufacturing models, designed before the pivotal process freezes.

Washington Redraws the Cell and Gene Therapy Supply Map

The Section 232 regime imposes duties of up to 100% on certain patented pharmaceuticals, with reduced rates for some trading partners and onshoring plans. Cell and gene therapies sit in a specialty category eligible for a zero rate, but that needs product-level legal review, and relief for a finished therapy should not be assumed to cover every imported input.

The BIOSECURE Act, signed on December 18, 2025, as part of the defense authorization law, restricts federal contracting and funding involving listed biotechnology companies of concern, with implementation unfolding over several years. For a sector relying on a narrow base of vector, plasmid and reagent suppliers, the sensible response is mapping exposure down to sub-tier vendors now. On the demand side, CMS said in October 2026 that it will extend its Medicaid Cell and Gene Therapy Access Model beyond sickle cell disease. Outcomes-based contracts will reward sponsors whose manufacturing records and patient follow-up systems can work together.

The Factory Inside the Patient: In Vivo CAR-T as a Capacity Wild Card

Any long-range capacity plan must account for therapies that generate CAR-T cells inside the body. Large pharma has committed billions through acquisitions and licensing, and early data have shown tumor clearance in multiple myeloma with lentiviral approaches. Durability, redosing and insertional risk remain open questions, and much of the field is still in phase 1.

In vivo approaches would not abolish manufacturing. They move complexity from patient cells to vectors, nucleic acids, formulation and analytics, a shift that favors true scale-up. Leaders should be wary of stranding capital in long-lived, single-purpose cell suites. Flexible facilities, conservative depreciation assumptions and deep vector expertise would hold value under either outcome.

Conclusion: Build the Cell and Gene Therapy Network Before the Forecast Demands It

Global success in this field will not come from bigger plants alone. It will come from treating manufacturing architecture as a market access decision, made early and revisited often. The winners will know their true cost per patient, their real turnaround time and their exposure at every supplier tier. For American pharma leaders, the opportunity is to turn a scientific lead into durable, worldwide reach, and that work begins well before the first commercial batch.

FAQ

Why is scaling autologous cell therapy so difficult?

Each batch serves one patient, so capacity grows through parallel suites, staff and testing rather than larger equipment.

Does automation solve the cost problem?

Only in part. It improves consistency and throughput, but vector, reagents and quality testing remain major cost drivers.

What does FDA's CMC flexibility guidance change?

It offers more latitude on qualification batch numbers, phase-appropriate CGMP and certain validation and comparability expectations, subject to scientific justification.

Could in vivo CAR-T make current facilities obsolete?

Possibly in part, but the evidence is early. Capacity plans should stay flexible until durability and safety are clearer.

What should a global manufacturing plan settle first?

Network model, vector supply, analytics and supplier exposure, ideally before the pivotal process is locked.